Here's the Deal
Baird's Investment Banking Group is pleased to announce the following transaction:
Vigene Biosciences, Inc. (“Vigene” or the “Company”), a portfolio company of Signet Healthcare Partners (“Signet”), has signed a definitive agreement to be acquired by Charles River Laboratories International, Inc. (“Charles River”) (NYSE: CRL). The purchase price is expected to be $292.5 million in cash, subject to customary closing adjustments. In addition to the initial purchase price, the transaction includes contingent additional payments of up to $57.5 million based on future performance. The transaction is expected to close in the beginning of the third quarter of 2021, subject to regulatory requirements and customary closing conditions.
Vigene is a premier, gene therapy contract development and manufacturing organization (CDMO) providing viral vector-based gene delivery solutions. Vigene’s primary area of expertise is CGMP viral vector manufacturing, which is used for gene therapies and gene-modified cell therapies. Vigene has significant expertise in adeno-associated virus (AAV) CGMP production, which is the most commonly used delivery solution for gene therapies, as well as for other major viral vectors, including lentivirus. Vigene also offers high-quality, research grade and CGMP plasmid DNA, which is a foundational tool used in the development of viral vectors for gene-modified cell therapies, gene therapies, and vaccine production. The Company is headquartered in Rockville, Maryland.
Signet Healthcare Partners is a leading provider of growth capital to innovative healthcare companies around the world. Signet invests in commercial-stage healthcare companies that are revenue generating or preparing for commercial launch, focusing primarily on the pharmaceutical and medical technology sectors. Signet is an active investor and partners closely with management teams to support growth and build successful businesses. Signet is headquartered in New York, New York.
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Charles River's dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. Charles River is headquartered in Wilmington, Massachusetts.
For additional information about this transaction, please contact: